Goldman Sachs reduces share in Orphazyme and drops below 5 percent boundary

Orphazyme's life on the stock exchange has been hectic in recent weeks.


US company Goldman Sachs has divested shares in Danish biotech firm Orphazyme, and as of June 17, owns less than 5 percent of the company, Orphazyme reported on Wednesday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs